ABCG2 and laryngeal carcinoma: A study had developed liposome-encapsulated DTX and siRNA against the ABCG2 gene (ABCG2-siRNA) which were used in combination therapy and could be targeted to the EGFR receptor on the surface of Hep-2 laryngeal cancer cells by conjugating GE11 peptide, which had significantly enhanced apoptotic effects and antitumor activities (Xu et al., 2017).